CytoSorb
Commercial- Indications
- Sepsis, Septic shock, Acute respiratory distress syndrome, Acute liver disease, Trauma, Burn injury, Pancreatitis
Company intelligence / Profile preview
Converge Biotech
Hyderabad, Telangana, Indiaconvergebio.in ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Converge Biotech has launched Vergiflu (Favipiravir 200 mg) in India for treating mild to moderate COVID-19 patients. The company also received FDA Emergency Use Authorization for a single-use, OTC PCR COVID-19 at-home test.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculesAntibodiesmRNA vaccinesProteins
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
TevaCompugenBiomX
Beyond the preview
Go deeper on Converge Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Converge Biotech.